Dr. Churchill et al., A phase I/II study of the safety and activity of a microsphere formulationof KNI-272 in patients with HIV-1 infection, J ANTIMICRO, 47(3), 2001, pp. 353-355
Eighteen patients with symptomatic HIV disease were enrolled into a phase I
/II study of a microsphere formulation of the HIV protease inhibitor KNI-27
2, with doses escalated up to a maximum dose of 60 mg/kg/day. One patient d
eveloped reversible elevation in hepatic transaminase. The plasma half-life
of the drug was very short, varying between 0.25 and 1.1 h. No consistent
effect on plasma HIV RNA levels or CD4(+) lymphocyte counts was seen.